MSD and Adcock Ingram intend to co-promote and distribute products from various therapeutic areas including: asthma, dermatology, hypercholesterolemia, hypertension, migraine and osteoporosis as well as a portfolio of OTC medications.
Stefan Oschmann, president of emerging markets for MSD, said: “The collaboration announced today is part of Merck’s long-term strategy of expanding our geographic presence. We expect sales from these markets to be a key contributor to our future performance and growth. As part of our pursuit of that growth we will strive to expand our presence across emerging markets by actively seeking local collaborations.
“This collaboration, with a highly respected local partner, shows our commitment to invest in South Africa. It also better positions us to address the serious burden of disease in the country and provide the people and patients of South Africa with access to affordable, high-quality health care.”
Jonathan Louw, CEO of Adcock Ingram, said: “We are excited about the collaboration with MSD because it will enhance our diverse portfolio and broaden our pipeline of new products in the market place.
“Together, we have a formidable marketing and distribution capacity backed by an excellent track record of delivery to all our clients.”